A recent phase II study (NCT04303741) employed CAMRELIZUMAB (an anti-PD-1 antibody) in combination with APATINIB (a tyrosine kinase inhibitor specifically directed against VEGFR2) and ERIBULIN (an inducer of tumor vessel normalization) [151]. This evidence concerns the gene KDR and neoplasm.